X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-04-01 | BEAM | Beam Therapeutics Inc. | Bellon Christine | GC | S - Sale | $18.35 | -5,674 | 117,294 | -5% | -$104,122 | ||||||
2025-04-01 | BEAM | Beam Therapeutics Inc. | Evans John M. | CEO | S - Sale | $18.35 | -30,663 | 1,089,249 | -3% | -$562,684 | ||||||
2025-04-01 | BEAM | Beam Therapeutics Inc. | Ciaramella Giuseppe | Pres | S - Sale | $18.35 | -7,434 | 190,216 | -4% | -$136,418 | ||||||
2025-04-01 | BEAM | Beam Therapeutics Inc. | Cavanagh Bethany J | SVP, Finance, Treasurer | S - Sale | $18.35 | -3,015 | 44,512 | -6% | -$55,330 | ||||||
| M | 2025-04-01 | BEAM | Beam Therapeutics Inc. | Simon Amy | Chief Medical Officer | S - Sale | $17.92 | -30,563 | 65,742 | -32% | -$547,835 | |||||
2025-04-03 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $2.24 | +1,200 | 109,620 | +1% | +$2,688 | ||||||
| M | 2025-03-31 | ADVM | Adverum Biotechnologies, Inc. | Leonard Braden Michael | 10% | P - Purchase | $4.23 | +34,775 | 5,641,643 | +1% | +$147,076 | |||||
2025-04-01 | HALO | Halozyme Therapeutics, Inc. | Henderson Jeffrey William | Dir | S - Sale | $64.05 | -503 | 33,108 | -1% | -$32,217 | ||||||
2025-03-27 | RLAY | Relay Therapeutics, Inc. | Bergstrom Donald A | Pres, R, D | S - Sale | $2.84 | -986 | 615,052 | 0% | -$2,800 | ||||||
2025-03-27 | RLAY | Relay Therapeutics, Inc. | Rahmer Peter | See remarks | S - Sale | $2.84 | -247 | 402,184 | 0% | -$701 | ||||||
2025-03-27 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $2.84 | -4,864 | 374,567 | -1% | -$13,814 | ||||||
2025-03-27 | RLAY | Relay Therapeutics, Inc. | Adams Brian | GC | S - Sale | $2.84 | -298 | 405,972 | 0% | -$846 | ||||||
| D | 2025-03-26 | SRZN | Surrozen, Inc./De | Column Group III Gp, LP | 10% | P - Purchase | $11.60 | +1,034,482 | 1,844,570 | +128% | +$11,999,991 | |||||
| D | 2025-03-27 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $6.04 | -138,574 | 1,117,450 | -11% | -$836,987 | |||||
2025-03-26 | TARA | Protara Therapeutics, Inc. | Zummo Jacqueline | Chf Scientific Operations Off | S - Sale | $4.53 | -21,224 | 98,861 | -18% | -$96,145 | ||||||
2025-03-26 | DTIL | Precision Biosciences Inc | Buehler Kevin | Dir | P - Purchase | $4.67 | +4,523 | 13,235 | +52% | +$21,122 | ||||||
2025-03-26 | DTIL | Precision Biosciences Inc | Brown Melinda | Dir | P - Purchase | $4.75 | +1,839 | 9,057 | +25% | +$8,735 | ||||||
2025-03-26 | KLRS | Kalaris Therapeutics, Inc. | Hagen Brett R | Chief Accounting Officer | S - Sale | $8.97 | -907 | 1,925 | -32% | -$8,135 | ||||||
| M | 2025-03-26 | ADVM | Adverum Biotechnologies, Inc. | Leonard Braden Michael | 10% | P - Purchase | $5.11 | +37,000 | 2,864,561 | +1% | +$188,931 | |||||
2025-03-25 | DTIL | Precision Biosciences Inc | Germano Geno J | Dir | P - Purchase | $5.30 | +3,250 | 11,057 | +42% | +$17,225 | ||||||
| D | 2025-03-24 | ADPT | Adaptive Biotechnologies Corp | Robins Harlan S | Chief Scientific Officer | S - Sale+OE | $9.00 | -1,698 | 1,279,524 | 0% | -$15,282 | |||||
2025-03-24 | TARS | Tarsus Pharmaceuticals, Inc. | Azamian Bobak R. | Pres, CEO, Board Chair | S - Sale | $50.00 | -6,000 | 877,741 | -1% | -$300,000 | ||||||
| D | 2025-03-24 | SRRK | Scholar Rock Holding Corp | Sacco Tracey | CHIEF COMMERCIAL OFFICER | S - Sale+OE | $33.08 | -6,500 | 71,750 | -8% | -$215,014 | |||||
| D | 2025-03-24 | SRRK | Scholar Rock Holding Corp | Moore Erin | Interim PFO, PAO | S - Sale+OE | $33.12 | -13,564 | 82,609 | -14% | -$449,237 | |||||
2025-03-24 | GLUE | Monte Rosa Therapeutics, Inc. | Leo Chandra P. | Dir | P - Purchase | $5.84 | +10,000 | 10,000 | New | +$58,383 | ||||||
| D | 2025-03-24 | DTIL | Precision Biosciences Inc | Amoroso Michael | Pres, CEO | S - Sale+OE | $5.56 | -964 | 109,540 | -1% | -$5,360 | |||||
| D | 2025-03-21 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $41.23 | -10,031 | 280,707 | -3% | -$413,578 | |||||
| D | 2025-03-21 | CRSP | Crispr Therapeutics AG | Bruno Julianne | COO | S - Sale+OE | $41.23 | -1,714 | 17,632 | -9% | -$70,668 | |||||
| D | 2025-03-21 | CRSP | Crispr Therapeutics AG | Prasad Raju | CFO | S - Sale+OE | $41.23 | -2,197 | 16,767 | -12% | -$90,582 | |||||
| D | 2025-03-21 | CRSP | Crispr Therapeutics AG | Kasinger James R. | GC, Secretary | S - Sale+OE | $41.23 | -3,185 | 81,729 | -4% | -$131,318 | |||||
2025-03-20 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale | $38.71 | -2,041 | 57,723 | -3% | -$79,008 | ||||||
2025-03-20 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $41.68 | -230 | 111,662 | 0% | -$9,585 | ||||||
2025-03-20 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $41.68 | -291 | 130,621 | 0% | -$12,128 | ||||||
| D | 2025-03-20 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $41.68 | -1,726 | 660,966 | 0% | -$71,933 | |||||
| D | 2025-03-19 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | S - Sale+OE | $18.92 | -21,000 | 3,786,233 | -1% | -$397,320 | |||||
| M | 2025-03-18 | TARS | Tarsus Pharmaceuticals, Inc. | Mottiwala Aziz | Chief Commercial Officer | S - Sale | $47.88 | -10,565 | 65,057 | -14% | -$505,856 | |||||
| M | 2025-03-18 | TARS | Tarsus Pharmaceuticals, Inc. | Neervannan Seshadri | COO | S - Sale | $47.89 | -7,583 | 79,682 | -9% | -$363,142 | |||||
| M | 2025-03-18 | TARS | Tarsus Pharmaceuticals, Inc. | Wahl Bryan | GC | S - Sale | $47.88 | -9,686 | 51,712 | -16% | -$463,766 | |||||
| M | 2025-03-18 | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | CHRO | S - Sale | $47.88 | -6,711 | 46,355 | -13% | -$321,323 | |||||
| M | 2025-03-18 | TARS | Tarsus Pharmaceuticals, Inc. | Azamian Bobak R. | Pres, CEO, Board Chair | S - Sale | $48.03 | -24,216 | 883,741 | -3% | -$1,163,050 | |||||
| M | 2025-03-18 | TARS | Tarsus Pharmaceuticals, Inc. | Farrow Jeffrey S | See Remarks | S - Sale | $47.88 | -3,724 | 22,431 | -14% | -$178,306 | |||||
2025-03-19 | BDTX | Black Diamond Therapeutics, Inc. | Biotech Growth N V | 10% | S - Sale | $2.07 | -5,784,292 | 2,733,547 | -68% | -$11,997,749 | ||||||
| M | 2025-03-18 | ADVM | Adverum Biotechnologies, Inc. | Leonard Braden Michael | 10% | P - Purchase | $4.98 | +117,941 | 5,519,722 | +2% | +$587,575 | |||||
| D | 2025-03-18 | CADL | Candel Therapeutics, Inc. | Nichols William Garrett | Chief Medical Officer | S - Sale+OE | $8.76 | -45,316 | 52,493 | -46% | -$396,995 | |||||
| D | 2025-03-18 | CADL | Candel Therapeutics, Inc. | Barone Francesca | Chief Scientific Officer | S - Sale+OE | $8.76 | -32,146 | 96,527 | -25% | -$281,673 | |||||
| M | 2025-03-18 | CADL | Candel Therapeutics, Inc. | Tak Paul Peter | CEO | S - Sale | $8.77 | -26,172 | 225,740 | -10% | -$229,624 | |||||
| AD | 2025-03-17 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | CTO | S - Sale+OE | $8.82 | -31,278 | 85,512 | -27% | -$275,947 | |||||
| D | 2025-03-17 | IMCR | Immunocore Holdings Plc | Baker Bros. Advisors LP | Dir | P - Purchase | $29.72 | +807,338 | 2,144,060 | +60% | +$23,993,224 | |||||
2025-03-17 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale | $39.04 | -1,458 | 59,764 | -2% | -$56,921 | ||||||
2025-03-17 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale | $39.04 | -11,738 | 948,016 | -1% | -$458,255 | ||||||
2025-03-17 | RVMD | Revolution Medicines, Inc. | Anders Jack | CFO | S - Sale | $39.04 | -1,864 | 115,006 | -2% | -$72,771 | ||||||
2025-03-17 | RVMD | Revolution Medicines, Inc. | Horn Margaret A | COO | S - Sale | $39.04 | -3,058 | 153,533 | -2% | -$119,385 | ||||||
2025-03-17 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale | $39.04 | -3,294 | 293,051 | -1% | -$128,599 | ||||||
2025-03-17 | SRRK | Scholar Rock Holding Corp | Peng Katie | Dir | S - Sale | $34.42 | -1,006 | 30,319 | -3% | -$34,627 | ||||||
| D | 2025-03-17 | RGEN | Repligen Corp | Hunt Anthony | Dir | S - Sale+OE | $152.51 | -26,756 | 136,301 | -16% | -$4,080,663 | |||||
| D | 2025-03-17 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | CTO | S - Sale+OE | $8.82 | -31,278 | 85,512 | -27% | -$275,947 | |||||
2025-03-17 | CADL | Candel Therapeutics, Inc. | Schoch Charles | See Remarks | S - Sale | $8.83 | -5,000 | 38,038 | -12% | -$44,169 | ||||||
| D | 2025-03-18 | ACLX | Arcellx, Inc. | Patel Kavita | Dir | S - Sale+OE | $71.64 | -1,500 | 0 | -100% | -$107,460 | |||||
| D | 2025-03-17 | CRSP | Crispr Therapeutics AG | Prasad Raju | CFO | S - Sale+OE | $41.80 | -3,762 | 12,714 | -23% | -$157,252 | |||||
2025-03-14 | ALLO | Allogene Therapeutics, Inc. | Chang David D | Pres, CEO | S - Sale | $1.96 | -46,668 | 8,189,765 | -1% | -$91,469 | ||||||
2025-03-14 | ALLO | Allogene Therapeutics, Inc. | Beneski Benjamin Machinas | SVP, Chief Technical Officer | S - Sale | $1.98 | -5,488 | 218,507 | -2% | -$10,839 | ||||||
2025-03-17 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $110.53 | -2,500 | 170,674 | -1% | -$276,325 | ||||||
| D | 2025-03-17 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $28.00 | -1,000 | 0 | -100% | -$28,000 | |||||
2025-03-14 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $40.05 | -92 | 111,892 | 0% | -$3,684 | ||||||
2025-03-17 | RGEN | Repligen Corp | Pax Margaret | Dir | P - Purchase | $150.69 | +250 | 1,043 | +32% | +$37,673 | ||||||
2025-03-13 | ADPT | Adaptive Biotechnologies Corp | Griffin Michelle Renee | Dir | S - Sale | $7.19 | -36,291 | 15,394 | -70% | -$260,932 | ||||||
2025-03-17 | ATYR | Atyr Pharma Inc | Gross Jane A | Dir | P - Purchase | $4.00 | +3,750 | 9,750 | +63% | +$15,000 | ||||||
2025-03-14 | CRBU | Caribou Biosciences, Inc. | Haurwitz Rachel E. | Pres, CEO | P - Purchase | $1.02 | +20,000 | 3,664,845 | +1% | +$20,400 | ||||||
2025-03-12 | TVGN | Tevogen Bio Holdings Inc. | Flomenberg Neal | See Remarks | S - Sale | $1.09 | -232,968 | 3,595,608 | -6% | -$253,935 | ||||||
| DM | 2025-03-12 | VCEL | Vericel Corp | Colangelo Dominick | Pres, CEO | S - Sale+OE | $46.05 | -53,183 | 259,997 | -17% | -$2,448,811 | |||||
2025-03-11 | CDTX | Cidara Therapeutics, Inc. | Ward Shane | COO, CLO | S - Sale | $21.96 | -1,664 | 14,674 | -10% | -$36,542 | ||||||
2025-03-11 | CDTX | Cidara Therapeutics, Inc. | Tari Leslie | CHIEF SCIENTIFIC OFFICER | S - Sale | $21.96 | -1,773 | 16,288 | -10% | -$38,940 | ||||||
2025-03-13 | KRYS | Krystal Biotech, Inc. | Krishnan Suma | Pres, R, D, 10% | S - Sale | $177.79 | -50,000 | 3,136,767 | -2% | -$8,889,525 | ||||||
2025-03-13 | KRYS | Krystal Biotech, Inc. | Krishnan Krish S | Pres, CEO, 10% | S - Sale | $177.79 | -50,000 | 3,136,767 | -2% | -$8,889,525 | ||||||
2025-02-03 | ELUT | Elutia Inc. | Highcape Capital, L.P. | Dir, 10% | P - Purchase | $2.50 | +420,000 | 9,520,232 | +5% | +$1,050,000 | ||||||
2025-02-03 | ELUT | Elutia Inc. | Highcape Capital, L.P. | Dir, 10% | P - Purchase | $2.50 | +420,000 | 9,520,232 | +5% | +$1,050,000 | ||||||
2025-03-11 | SLDB | Solid Biosciences Inc. | Kahn Clare | Dir | P - Purchase | $5.34 | +1,860 | 2,960 | +169% | +$9,924 | ||||||
2025-03-12 | ADPT | Adaptive Biotechnologies Corp | Hershberg Robert | Dir | S - Sale | $7.59 | -53,000 | 69,690 | -43% | -$402,270 | ||||||
| D | 2025-03-10 | ADPT | Adaptive Biotechnologies Corp | Neupert Peter M | Dir | S - Sale+OE | $7.05 | -10,000 | 224,690 | -4% | -$70,500 | |||||
| D | 2025-03-10 | IPSC | Century Therapeutics, Inc. | Pfeiffenberger Brent | Pres, CEO | S - Sale+OE | $0.62 | -2,235 | 1,711,810 | 0% | -$1,375 | |||||
| D | 2025-03-10 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | See Remarks | S - Sale+OE | $0.62 | -2,360 | 485,346 | 0% | -$1,451 | |||||
| D | 2025-03-10 | IPSC | Century Therapeutics, Inc. | Farid Adrienne | Chief Operations Officer | S - Sale+OE | $0.62 | -2,359 | 251,717 | -1% | -$1,451 | |||||
| D | 2025-03-10 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale+OE | $0.62 | -1,240 | 411,181 | 0% | -$763 | |||||
| D | 2025-03-10 | SRRK | Scholar Rock Holding Corp | Myles Edward H | COO, CFO | S - Sale+OE | $35.62 | -142,292 | 111,345 | -56% | -$5,068,974 | |||||
| DM | 2025-03-11 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $42.70 | -14,435 | 271,050 | -5% | -$616,349 | |||||
| DM | 2025-03-11 | CRSP | Crispr Therapeutics AG | Kasinger James R. | GC, Secretary | S - Sale+OE | $42.67 | -3,966 | 78,664 | -5% | -$169,242 | |||||
| DM | 2025-03-11 | CRSP | Crispr Therapeutics AG | Bruno Julianne | COO | S - Sale+OE | $42.54 | -1,388 | 15,596 | -8% | -$59,050 | |||||
| D | 2025-03-10 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale+OE | $118.17 | -17,929 | 173,174 | -9% | -$2,118,696 | |||||
| M | 2025-03-07 | TVGN | Tevogen Bio Holdings Inc. | Flomenberg Neal | See Remarks | S - Sale | $1.09 | -211,909 | 3,828,576 | -5% | -$231,734 | |||||
2025-03-07 | IMVT | Immunovant, Inc. | Fromkin Andrew J. | Dir | S - Sale | $19.60 | -8,000 | 91,913 | -8% | -$156,769 | ||||||
2025-03-10 | TNYA | Tenaya Therapeutics, Inc. | Higa Tomohiro | SVP, Finance | S - Sale | $0.54 | -2,482 | 99,690 | -2% | -$1,336 | ||||||
2025-03-10 | TNYA | Tenaya Therapeutics, Inc. | Tingley Whittemore | Chief Medical Officer | S - Sale | $0.54 | -7,398 | 174,793 | -4% | -$3,983 | ||||||
2025-03-10 | TNYA | Tenaya Therapeutics, Inc. | Ali Faraz | CEO | S - Sale | $0.54 | -9,741 | 320,514 | -3% | -$5,245 | ||||||
2025-03-07 | BIIB | Biogen Inc. | Sherwin Stephen A | Dir | S - Sale | $150.02 | -8,760 | 11,318 | -44% | -$1,314,142 | ||||||
2025-03-06 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $40.91 | -918 | 130,912 | -1% | -$37,558 | ||||||
2025-03-06 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $40.91 | -277 | 111,984 | 0% | -$11,333 | ||||||
| D | 2025-03-06 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $40.91 | -2,402 | 662,692 | 0% | -$98,273 | |||||
2025-03-06 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $40.91 | -241 | 51,434 | 0% | -$9,860 | ||||||
2025-03-05 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale | $30.48 | -1,590 | 251,033 | -1% | -$48,463 | ||||||
2025-03-05 | APGE | Apogee Therapeutics, Inc. | Henderson Michael Thomas | CEO | S - Sale | $30.15 | -10,000 | 1,292,987 | -1% | -$301,511 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |